More than 50% of human cancers, including prostate cancer, exhibit loss of normal p53 functions and/or defects in the p53 signaling pathway as well as missense mutations or deletions; these molecular alterations are associated with resistance to cell death [4], [5]. This evidence concerns the gene TP53 and prostate carcinoma.